The host response and molecular pathogenesis associated with respiratory syncytial virus infection.
about
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial VirusRespiratory Syncytial Virus (RSV) Modulation at the Virus-Host Interface Affects Immune Outcome and Disease PathogenesisDevelopment of asthma is determined by the age-dependent host response to respiratory virus infection: therapeutic implicationsRespiratory syncytial virus can infect basal cells and alter human airway epithelial differentiationControl of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection.Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus.Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressureReduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease.Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infectionProphylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.The infectious march: the complex interaction between microbes and the immune system in asthma.A prospective, open-label, non-comparative study of palivizumab prophylaxis in children at high risk of serious respiratory syncytial virus disease in the Russian Federation.The airway epithelium: soldier in the fight against respiratory virusesTherapeutic targeting of respiratory syncytial virus G-protein.Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.Nasal mucosal microRNA expression in children with respiratory syncytial virus infection.Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory TractAntibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in miceNeonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infantsHuman respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β.Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and ageAdvances in and the potential of vaccines for respiratory syncytial virus.Respiratory syncytial virus infection of airway cells: Role of microRNAs.The role of Th17 and Treg responses in the pathogenesis of RSV infection.Understanding respiratory syncytial virus (RSV) vaccine development and aspects of disease pathogenesis.Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection.Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.Atomic force microscopic investigation of respiratory syncytial virus infection in HEp-2 cells.Anti-viral activity of water extract of Paeonia lactiflora pallas against human respiratory syncytial virus in human respiratory tract cell lines.Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010-2013): age distribution, seasonality and association between prevalent genotypes and disease severity.Antiviral effect of cimicifugin from Cimicifuga foetida against human respiratory syncytial virus.Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication.Respiratory syncytial virus F and G proteins induce interleukin 1alpha, CC, and CXC chemokine responses by normal human bronchoepithelial cells.Monocyte differentiation toward regulatory dendritic cells is not affected by respiratory syncytial virus-induced inflammatory mediators.Distinct patterns of innate immune activation by clinical isolates of respiratory syncytial virus.His-tag based in situ labelling of progeny viruses for real-time single virus tracking in living cells.Human Respiratory Syncytial Virus: An Introduction.Novel clinical features of recurrent human respiratory syncytial virus infections.
P2860
Q26748856-E158897F-39D5-4D14-AADE-EDA43B94EF92Q26823449-297926AA-416A-4380-8C21-AD9650009070Q26991548-DC6EE720-FDDA-4AE3-8A02-D6538B65F9B7Q28540852-A7DFE54F-03DE-47AB-A092-FD0DA5374B3EQ30301182-A38CD8B4-B41B-42A0-9ED6-E89F6C503DF2Q30431134-1C96114E-FEA9-44E2-9AFC-BC6FEE26F9F9Q33558356-1997E9DD-4583-46FF-BA39-C4CD7AEB3353Q33744060-D9E9FE0B-24BA-4160-AA0C-BC6FC69F957EQ33840252-3F0302AB-5D8B-4E04-84AA-CECD5055418FQ33881536-CB591FD4-FF79-4E4A-9016-43C751DDDBCCQ34120278-2B89D5FD-2F62-4558-9F08-B55825C09079Q34262180-4D422AE2-374B-4FEE-BF33-705C762C9D9FQ34356430-8A0D20BC-8571-4984-96E6-F2F227D9EC3CQ34401644-44C236A4-D500-47C0-8B64-45A4AF314DE7Q34491598-A1936638-9229-40AE-AE58-24BF4E2E31FBQ34603346-050CED65-02CB-44A8-A346-4915A0018992Q34990420-F1ECDA19-835D-4453-8493-2D66E46B448EQ35293673-97900B41-B750-4623-9219-AD20EF57A018Q35690781-1C8B26D6-F0CC-4AE5-8436-583550FEE420Q36106575-4E072DF4-3C11-489D-9A7F-F434382D694DQ36482799-22A6BD28-8B8D-47C6-AE98-3883FE7D64F0Q36725539-EEFEAE37-0BEE-41DA-9702-C7A164C8FF60Q36977881-F8D180D4-7675-433E-AE90-227334712E02Q38130514-8B87D27A-6439-4D3D-B1A9-2B1B7EB0E6B1Q38408396-22212B02-531A-4B51-A011-4E90A18F9CFBQ38565395-CE4DFE4C-D92F-4271-9F34-45DF98121D42Q38660842-303B3B6B-B09C-4FE4-8CED-631D4F62D7C4Q38802215-4776B133-E4D1-4EE5-977D-A21DC2F42297Q39027049-D120BFE3-7AFA-468E-8921-A1C8420EFD1CQ39061469-41B03C18-4A1D-4235-98EA-8FDFA7C715F6Q39147032-1D635945-945C-4F4A-ABC0-890765597E62Q39260915-DB9C0849-A6B8-4CE7-A752-2D5E5AC4FCC9Q39289483-84A353AA-16FF-42CF-8E72-3EF1C3CBB3B4Q39297218-D328517A-3C97-4016-B63D-2EB71765B4D6Q39635571-11A01F23-2647-4006-B8CE-22BA95C65098Q39685989-ECAFC6A3-CF8E-4FEA-A79F-73ED455375C9Q40055725-63964DDF-BC3A-4BD0-982B-A55539A919B0Q40470131-B6C71D39-5C88-4C89-B54B-640E86ECC86DQ40597806-F54AE522-CF08-4594-AA69-50D3D52A9351Q41841268-A69C2830-2C4C-4B91-8D6B-ADEE278E6336
P2860
The host response and molecular pathogenesis associated with respiratory syncytial virus infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The host response and molecula ...... ory syncytial virus infection.
@en
The host response and molecula ...... ory syncytial virus infection.
@nl
type
label
The host response and molecula ...... ory syncytial virus infection.
@en
The host response and molecula ...... ory syncytial virus infection.
@nl
prefLabel
The host response and molecula ...... ory syncytial virus infection.
@en
The host response and molecula ...... ory syncytial virus infection.
@nl
P2093
P2860
P356
P1433
P1476
The host response and molecula ...... ory syncytial virus infection.
@en
P2093
Christine M Oshansky
Elizabeth Moore
Ralph A Tripp
Wenliang Zhang
P2860
P304
P356
10.2217/FMB.09.1
P577
2009-04-01T00:00:00Z